Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

Rock Bottom Prices May Tempt Big Pharma

Executive Summary

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

You may also be interested in...



How To Turn Around A Struggling Biotech

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.

Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?

Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel